Integra Lifesciences opened lower at $14.62, compared with its previous close of $14.77. In the last trading session, the stock traded between $14.13 and $14.93. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Integra Lifesciences is now worth
$ 21.17
Resulting in a loss of
$ 78.83 (78.83%)
Note: Past profits do not guarantee future returns.
Rating from 9 Analysts
Today's Change
$-0.40 (-2.70%)
Day High
$14.93
Day Low
$14.13
Day Open
$14.62
Prev Close
$14.77
Volume
7,20,344
1W Return
-3.08%
1M Return
2.79%
3M Return
-17.25%
6M Return
2.87%
1Y Return
16.55%
Market Cap ($ Mn)
1,118
PE Ratio
-
PB Ratio
1.26
PEG Ratio
-
ROE
-41.72%
ROCE
-16.08%
EPS (TTM)
$0.19
1 Week
-3.08%
1 Month
2.79%
3 Months
-17.25%
6 Months
2.87%
9 Months
28.54%
Integra LifeSciences CFO to present at UBS Global Healthcare Conference
Integra LifeSciences CFO Lea Knight will present at the 2026 UBS Global Healthcare Conference. The presentation is scheduled for Monday, November 9, 2026, at 2:45 pm ET. A live webcast will be available on the company's investor relations website.
6 days agoPomerantz investigates Integra LifeSciences over securities fraud claims
Pomerantz LLP is investigating Integra LifeSciences for alleged securities fraud. Stock dropped 21.2% on October 2, 2026, after revenue guidance was cut by $30.5 million. Q3 results confirmed a $411.2 million revenue miss due to Cincinnati facility flooding. Tissue Reconstruction segment saw a 2.2% organic revenue contraction amid competitive headwinds.
9 days agoIntegra LifeSciences Q3FY26 Results: Adj EPS beats, cash flow hits record
Revenue of $411.2 million missed consensus by 0.71%, impacted by $7 million from Cincinnati flood damage. Adjusted EPS of $0.59 beat estimates by 5.36%, supported by cost reductions and strong Neurosurgery growth. Operating cash flow reached a record $96 million, boosting liquidity despite operational disruptions. FY26 revenue guidance maintained at $1.634-$1.654 billion, with Q4 impact estimated at $15-$20 million. Debt refinancing completed for $2.1 billion, extending maturities but increasing interest expense in 2027.
22 days agoIntegra LifeSciences faces fourth securities probe after Q3 miss
Fourth law firm, Bragar Eagel & Squire, investigates Integra for securities law violations. Stock fell 21.2% after Q3 revenue missed consensus estimates of $416.3 million. Full-year revenue guidance cut to $1.634B-$1.654B due to Cincinnati facility flooding. Management previously stated no material impact expected, contradicting later disclosures.
1mo agoIntegra LifeSciences to present at Wells Fargo and Morgan Stanley healthcare conferences
CFO Lea Knight and CCO Michael McBreen to present at Wells Fargo conference on September 9, 2026. CEO Stuart Essig scheduled to speak at Morgan Stanley conference on September 15, 2026. Live webcasts of both presentations will be hosted on the investor relations website.
2mo agoIntegra Lifesciences Q3 Results: Sales guidance beats estimates
Integra Lifesciences forecasts Q3 adjusted EPS of $0.53-$0.61 and sales of $410-$425 million. The sales guidance exceeds the $418.100 million analyst estimate, while the EPS range brackets the $0.56 consensus, indicating stable profit expectations alongside potential revenue upside.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Integra Lifesciences is now worth
$ 21.17
Resulting in a loss of
$ 78.83 (78.83%)
Note: Past profits do not guarantee future returns.
